Bridging the interpretation gap in cancer genomics – the next frontier for ai in oncology
Can artificial intelligence finally unlock the full potential of cancer genomics? Discover how new digital tools are closing the gap between data and clinical action in oncology.
AI tool outperforms manual PD-L1 scoring in a study
Integrating artificial intelligence into pathology routine workflows could optimise patient selection for immunotherapy
Is there still a role for anti-TIGIT therapy in hepatocellular carcinoma?
While the IMbrave152/SKYSCRAPER-14 trial showed no added benefit with tiragolumab, other studies are ongoing to explore the potential of additional immune checkpoint inhibition in combination with standard therapy
AI may be key to streamline patient allocation to clinical trials
As a proof of concept, an AI-powered large language model matching platform shows promise in patient selection
How AI is expediting clinical research: the use of synthetic real-world data
While synthetic real-world data may help overcome current challenges in clinical trials, it also introduces new complexities
Dual targeted therapy shows promise in mestastatic clear cell renal cell carcinoma
The combination of lenvatinib plus everolimus improved progression-free survival in the LenCabo trial, but toxicity must be carefully assessed
Combination improves endocrine response after CDK4/6 inhibition in ER-positive, HER2-negative advanced breast cancer
In the evERA BC trial, giredestrant plus everolimus led to a prolonged progression-free survival
Data from two novel TEAD inhibitors provide the first evidence for the efficacy and safety of targeted treatments in mesothelioma
In early phase studies, IAG933 and VT3989 led to encouraging disease control rates with manageable toxicity
Rethinking the limits of tissue-agnostic cancer therapy
The promises of a tumour-agnostic oncology are still challenged by conventional clinical trial design and regulatory processes
ctDNA-guided adjuvant chemotherapy in colon cancer: not ready for prime time?
Two studies fail to meet their primary endpoints, reinforcing the need to improve the sensitivity of ctDNA testing before it enters the clinic